Short answer
Erasca, Inc. (ERAS) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$31M
- +1.9% YoY · +9.6% QoQ
- EPS (diluted)
- −$0.11
- −57.1% YoY · +8.3% QoQ
Source: XBRL data from the Erasca, Inc. (ERAS) Q3 2025 10-Q on SEC EDGAR. USD.
Erasca, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or changed risk factors reported versus 2024 10-K
- Clinical trial delays and regulatory approvals remain key operational risks impacting near-term milestones
- Dependence on a concentrated cash position, with liquidity sufficient through mid-2026 under current projections
- Intellectual property litigation risk ongoing, with no new material developments this quarter
- Competitive pressures from larger oncology firms persist, challenging clinical and commercial progress
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Erasca, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.